Affimed CEO Adi Hoess

Af­fimed spurs promis­ing re­sponse num­bers in NK cell study, but dura­bil­i­ty will be the big ques­tion

Ger­man biotech Af­fimed caught some at­ten­tion ear­li­er this year with a pair of com­plete re­spons­es in an ear­ly study of its NK cell reg­i­men for lym­phoma. The biotech is back with more da­ta from that study, and the re­sults look promis­ing — but will dura­bil­i­ty hold up?

A com­bi­na­tion reg­i­men of donor NK cells and Af­fimed’s CD30-tar­get­ing in­nate cell en­gager AFM13 spurred re­spons­es in 16 of 18 pa­tients with re­lapsed or re­frac­to­ry Hodgkin and non-Hodgkin lym­phomas, in­clud­ing sev­en com­plete re­spons­es, as part of the first of two rounds of treat­ment in a Phase I/II study, the biotech said Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.